BR112022019689A2 - Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer - Google Patents

Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer

Info

Publication number
BR112022019689A2
BR112022019689A2 BR112022019689A BR112022019689A BR112022019689A2 BR 112022019689 A2 BR112022019689 A2 BR 112022019689A2 BR 112022019689 A BR112022019689 A BR 112022019689A BR 112022019689 A BR112022019689 A BR 112022019689A BR 112022019689 A2 BR112022019689 A2 BR 112022019689A2
Authority
BR
Brazil
Prior art keywords
cytokine
masked
cytokines
cancer
kit
Prior art date
Application number
BR112022019689A
Other languages
English (en)
Portuguese (pt)
Inventor
Rozenfeld Raphael
Eskiocak Ugur
Qiu Huawei
Johnson Parker
Allen Jenkins Kurt
Pederzoli-Ribeil Magali
Singh Tomar Dheeraj
Kay O?Donnell Rebekah
Original Assignee
Xilio Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xilio Dev Inc filed Critical Xilio Dev Inc
Publication of BR112022019689A2 publication Critical patent/BR112022019689A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/10Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
BR112022019689A 2020-04-01 2021-03-31 Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer BR112022019689A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003824P 2020-04-01 2020-04-01
US202063118571P 2020-11-25 2020-11-25
PCT/US2021/025103 WO2021202675A1 (en) 2020-04-01 2021-03-31 Masked il-2 cytokines and their cleavage products

Publications (1)

Publication Number Publication Date
BR112022019689A2 true BR112022019689A2 (pt) 2022-12-20

Family

ID=77928454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019689A BR112022019689A2 (pt) 2020-04-01 2021-03-31 Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer

Country Status (13)

Country Link
US (1) US20230151072A1 (https=)
EP (1) EP4126247A4 (https=)
JP (1) JP7735306B2 (https=)
KR (1) KR20220161404A (https=)
CN (1) CN115942976A (https=)
AU (1) AU2021245922A1 (https=)
BR (1) BR112022019689A2 (https=)
CA (1) CA3172649A1 (https=)
IL (1) IL296915A (https=)
MX (1) MX2022012311A (https=)
PH (1) PH12022552627A1 (https=)
TW (1) TW202204388A (https=)
WO (1) WO2021202675A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2021254283B2 (en) * 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
JP2024511387A (ja) 2021-03-16 2024-03-13 シートムエックス セラピューティクス,インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
MX2024010488A (es) * 2022-02-28 2024-09-05 Xilio Dev Inc Citocinas dirigidas y metodos de uso de estas.
WO2023164286A1 (en) * 2022-02-28 2023-08-31 Xilio Development, Inc. Engineered cd122 compositions and methods thereof
KR20250039361A (ko) * 2022-07-15 2025-03-20 실리오 디벨럽먼트, 인크. 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법
CN117917438A (zh) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
TW202517789A (zh) * 2023-07-04 2025-05-01 香港商禮邦醫藥(香港)有限公司 Klk1融合蛋白質的製備方法
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025049948A1 (en) * 2023-08-30 2025-03-06 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EP2882775B1 (en) * 2012-08-09 2018-02-14 Roche Glycart AG Asgpr antibodies and uses thereof
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CN108218993B (zh) * 2018-01-05 2020-11-17 阿思科力(苏州)生物科技有限公司 一种以robo1为靶点的双特异性抗体及其制备和应用
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US12459980B2 (en) * 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN112867503A (zh) * 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
CN120463822A (zh) * 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
JP2022533254A (ja) 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス (ホン コン) リミテッド Il-2組成物およびその使用方法

Also Published As

Publication number Publication date
MX2022012311A (es) 2023-01-05
AU2021245922A1 (en) 2022-10-13
JP7735306B2 (ja) 2025-09-08
EP4126247A1 (en) 2023-02-08
PH12022552627A1 (en) 2023-01-04
US20230151072A1 (en) 2023-05-18
EP4126247A4 (en) 2024-04-24
CN115942976A (zh) 2023-04-07
WO2021202675A1 (en) 2021-10-07
KR20220161404A (ko) 2022-12-06
CA3172649A1 (en) 2021-10-07
TW202204388A (zh) 2022-02-01
JP2023520517A (ja) 2023-05-17
IL296915A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
BR112022019689A2 (pt) Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer
BR112022019789A2 (pt) Citocinas il-15 mascaradas, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, composição farmacêutica, kit e métodos de produção de uma citocina il-15 mascarada e de tratamento ou prevenção de câncer
BR112022019708A2 (pt) Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
EP4321530A3 (en) Masked cytokine polypeptides
BR112022014522A2 (pt) Compostos degradadores, composição farmacêutica, métodos para tratar transtornos, compostos
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
ECSP22029777A (es) Heterociclos bic?clicos como inhibidores de fgfr
SV2009003305A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BRPI0617162B8 (pt) compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
MX2009004699A (es) Compuestos de piridinona.
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
BR0317430A (pt) Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
BRPI0611620A2 (pt) mimÉticos de glicocorticàide, mÉtodos de fazÊ-los, composiÇÕes farmacÊuticas e usos dos mesmos
BR112022002196A2 (pt) Terapia de combinação envolvendo anticorpos contra claudina 18.2 e inibidores de ponto de checagem imunológico para tratamento de câncer
CR20220207A (es) Compuestos terapéuticos y métodos de uso
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0519690A2 (pt) composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
MX2024010488A (es) Citocinas dirigidas y metodos de uso de estas.
BRPI0308606B8 (pt) compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
BR112023020622A2 (pt) Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.